StrideBio
Durham
About StrideBio
StrideBio is a gene therapy company focused on developing genetic medicines with curative potential for patients with devastating conditions. It leverages its proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. The company was founded in 2015 and is headquartered in Durham, North Carolina.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $97.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2021)
- Website: stridebio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Information Technology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/stridebio-61725 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.